• Full service provider of start-up and clinical stage operations, strategy and
    corporate development capabilities

  • Unique depth and breadth of experience in corporate development, transactions,
    business operations, clinical project management, medicinal chemistry,
    computational approaches to compound library and drug design and synthesis, in
    vivo pharmacology, cell biology, corporate communications and intellectual
    property

  • Experienced management and leadership of lifesciences technology start-ups,
    biotechnology, pharmaceutical & molecular diagnostics ventures and their
    operating units

  • Business plan development, capital formation strategy and implementation
    (Angels, VCs and public capital markets)

  • Deal experience includes successful negotiation of high value transactions with
    AstraZeneca, Bayer, Bristol MyersSquibb, Celgene, Chiron, Daiichi-Sankyo,
    Genentech, Merck, Pfizer, Renovis and Sanofi-aventis, etc.

  • Experienced with all forms of business contracts including technology licenses,
    sponsored research, services agreements for IND-enabling studies, clinical trials,
    drug substance manufacturing, drug product formulation, offshore outsourcing,
    grant funding etc.

  • Through the exclusive relationship with its Bangalore-based affiliate, VentureEdge
    LLC identifies and leads partnership, licensing, outsourcing and strategic
    opportunities in India

  • High level contacts within biotech, big pharma and venture capital for the benefit
    of Clients
VentureEdge LLC All rights reserved. 2008-2012
At Renovis, where Dushyant was Vice President,
Corporate Development and an Officer of the Company,
after the acquisition of Centaur, he led the company's
business development ($180 million Pfizer alliance),
commercial planning (Ph 2 clinical project go / no-go
decision-making) and IND-track  & clinical project
operations (multiple IND, Ph1 and Ph2 single–site and
multi-center clinical trials) and was a member of the team
responsible for Renovis’ successful IPO in 2004.  In
addition to his strategic and operational roles at clinical-
stage companies, Dushyant has led and managed
companies at the start-up and early development stage
from business plan development onwards, including
BioProtocol (an information technology and software
services company) and Cellexicon (focused on molecular
diagnostics for early cancer detection) where he was
President & CEO.  

Dushyant received his M.B.A. from the Haas School of
Business at UC, Berkeley and his Ph.D. in Biochemistry,
Molecular Biology & Cell Biology from Northwestern
University. He conducted post-doctoral research as a
Damon Runyon-Walter Winchell Cancer Fund Fellow and
was a member of the Research Faculty at Yale University
/ HHMI prior to initiating his business career in venture
capital at Connecticut Innovations.Most recently he was
Vice President of Business Development at iPierian, an
iPSC (induced pluripotent stem cell) focused drug
discovery company where he helped formulate the
company’s strategic focus and laid the foundation for
TRANSACTIONS - BUSINESS OPERATIONS - PROACTIVE STRATEGY  
Dushyant Pathak is the founder of VentureEdge LLC and has over 20 years of
life-sciences domain expertise.
He is currently serving as Associate Vice Chancellor
of Technology Management & Corporate Relations
at University of California, Davis
where he is responsible for
InnovationAccess and the Office of Corporate
Relations
.  He has held senior management positions at both listed and private
biopharmaceutical companies including Chiron, Axys Pharmaceuticals, Centaur
Pharmaceuticals, Renovis and iPierian where he was responsible for negotiating
and closing a number of high value transactions as well as managing business
and clinical project operations.  His experience spans CEO and senior corporate
development and operational roles in the biotech and diagnostics.
further non-dilutive funding by leading the company’s successful application under the government
GO grant initiative.  Additionally, Dushyant built multiple critical relationships with academic and
commercial institutions to build the company’s proprietary, commercial-use consented, patient-
derived asset base.   He was with the company through its growth from fewer than 20 employees
to almost 60, during which period the company merged with another and raised two rounds of
equity capital in a difficult financing market.  Prior to iPierian, Dushyant was President and CEO of
Cellexicon, a cancer focused biomarker discovery and early-detection molecular diagnostics start-
up with research labs in San Diego.
  • Steve Carlson
    Facilities Set-up, Management,
    Operations, GMP / GLP
  • Stefan Hemmerich
    Clinical Operations, Project
    Management, Regulatory Affairs
  • Hal Kane
    Strategic Writer, Media Relations,
    PR, Ghost Writing, Speech Writing
  • John Kincaid
    Synthetic Medicinal Chemistry, Pre-
    clinical Development
  • Sunil Singh
    Patent Attorney, Intellectual Property
    Strategy, Drafting, Chemistry
  • Herbert Treutlein
    Computational Biology & Chemistry,
    Drug Design, Molecular Modeling
Dushyant is closely involved with the local community.  He serves as an Adjunct
Professor in the MBA for Executives program at the University of San Francisco's
School of Business & Management and has taught in the full-time and executive
MBA programs at the Walter Haas School of Business at UC, Berkeley.  He is
currently serving as the first Entrepreneur-in-Residence at Mission Bay Capital, as part of the
University of California's QB3
Innovation Toolkit for entrepreneurs, students, postdocs and faculty.  
He has also been entrepreneur-in-residence at the Lester Center for Entrepreneurship &
Innovation at the Haas School of Business.  Additionally, he is on the Board of Directors of
Creativity Explored, a San Francisco based not-for-profit organization that assists developmentally
disabled artists by providing studio access, artist resources and gallery space to enable them to
create, exhibit and sell original works of art.
  • Catherine Magill
    Prelinical Pharmacology and Cell
    Biology, Project Management
  • Ravi Upasani
    Patent Agent, Drafting, FTO, Patent
    Diligence, SAR / IP strategy
  • Karen Meier
    Regulatory Affairs, Medical Writing,
    Project Management